semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  HIV Infections Papilloma Women may be eligible for this study if they Are HIV-positive Are at least 13 years of age and menstruating Are willing to enroll in another drug study Have written consent of a parent or guardian if under 18 years This study has been changed to increase enrollment. Women who are starting HAART-based therapy prescribed by a personal physician or participating in an antiretroviral trial are all eligible Intend to start antiretroviral therapy within 14 days of study entry  Women will not be eligible for this study if they Have been on anti-HIV treatment for more than 14 days Are abusing drugs or alcohol Are receiving medication that affects the immune system, fights HPV, or is investigational, except for anti-HIV drugs provided by coenrolling in a Phase II or III trial with approval of a study chair within 30 days of study entry, including but not limited to systemic interferons and interleukins, thalidomide, systemic cidofovir, and HPV vaccines. This study has been changed. The following medications are no longer excluded: thymopentin, hydroxyurea, granulocyte colony-stimulating factor (G-CSF and filgrastim), and GM-CSF (sargramostim) Have cervical cancer or a history of cervical cancer Have had a hysterectomy (removal of the uterus) Participated in HPV trials at any time Use imiquimod inside the vagina Are taking corticosteroid treatment in large doses
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically or cytologically confirmed stage IIB-IVA carcinoma of the cervix Adenocarcinoma Squamous cell carcinoma Mixed cell histology No small cell anaplastic histology No para-aortic lymph node involvement No indication for para-aortic radiotherapy No distant metastases No CNS disease Age and over Performance status
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anal Cancer Cervical Cancer Esophageal Cancer Head and Neck Cancer Penile Cancer Vulvar Cancer Histologically proven stage III, IV, or recurrent carcinoma of the cervix or other tumor that carries human papilloma virus 16 (HPV16) such as other anogenital (vulvar, penile, and anal), esophageal, and head and neck cancers HLA-A2.1 positive Patients with tumors other than cervical cancer must have no other therapeutic options Fresh tissue or paraffin block available for HPV genome detection and typing (optional for cervical cancer) No history of CNS metastases Age Over 18 Performance status ECOG 0-1 Life expectancy More than 3 months Hematopoietic WBC at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Cervical Cancer Histologically confirmed cervical cancer, including the following subtypes Squamous cell carcinoma Adenosquamous cell carcinoma Adenocarcinoma (excluding small cell, clear cell, and other rare variants of the classical adenocarcinoma) FIGO stage IB2, IIA (greater than 4 cm), or IIB Age to 75 Performance status WHO 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count greater than 1,500/mm^3 Platelet count greater than 100,000/mm^3 Hepatic
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed stage IB2 invasive carcinoma of the uterine cervix of one of the following types Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Primary, previously untreated disease Exophytic cervical lesions greater than 4 cm in diameter OR Cervical expansion to greater than 4 cm in diameter, presumed to be the result of principal involvement with cancer No evidence of extrauterine disease other than pelvic lymph node involvement (by clinical and radiographic examinations) No para-aortic lymph nodal disease (suspected on CT scan, MRI, positron-emission tomography, or lymphangiogram) unless nodes are confirmed to be pathologically negative (by CT-guided biopsy or extraperitoneal lymph node dissection) Eligible for radical hysterectomy and lymph node dissection Age
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pregnancy Women of child bearing age Not pregnant Interested in delaying pregnancy using oral contraceptives or a depo-provera shot Had sex in the last month or are planning to have sex in the next month Have not used contraception during every sexual encounter within 3 months prior to study entry
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Squamous Cell Carcinoma Stage I Cervical Cancer Diagnosis of carcinoma of the cervix of 1 of the following cellular types Squamous cell carcinoma Adenocarcinoma Adenosquamous cell carcinoma Stage IB1 disease (no greater than 4 cm) No unequivocal evidence of metastases Adequate surgical candidate No known allergy to triphenylmethane compounds No prior pelvic irradiation No prior retroperitoneal surgery
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervix Neoplasms Stage Ib1-IVa cervical cancer Treatment with concurrent chemotherapy and radiation at the University of Iowa Hospitals and Clinics  Immunosuppressive disorders Use of immunosuppressive medications Transplant recipient Metastatic or recurrent cervical cancer History of any other type of cancer
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-23.0,  Cervical Cancer Genital Warts Female with an intact uterus with lifetime history of 0-4 sexual partners  Prior Human Papillomavirus (HPV) vaccination Prior abnormal paps History of genital warts
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Papillomavirus Infections Willing to be on acceptable method of birth control Have a Pap smear result of LSIL or ASCUS Is high risk HPV positive  No evidence of high-grade disease or glandular abnormalities Complete visualization of all lesion margins and the transformation zone No uncontrolled significant medical illness or sexually transmitted infections Taking any restricted medications such as interferon, immunomodulators, cytotoxic drugs, investigational drugs, steroids
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cervix Neoplasms Women with ONLY the following results on a routine Pap smear Low grade epithelial abnormality Minor changes in squamous cell Minor changes in squamous cells with appearances consistent with Papillomavirus Women aged between 18-70 years  Women who are pregnant or planning to become pregnant in the next 12 months Women with previous Pap smear abnormality for 2 years
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervix Cancer Cervical cancer undergoing primary radiotherapy  Stage 1B Patient refusal
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-25.0,  Cervical Cancer Precancerous Condition •Healthy participants Deemed to be in good general health by history and physical examination •Resident of Guanacaste Province of Costa Rica and surrounding areas Must remain a resident for ≥ 6 months after the first study vaccination Age to 25 Performance status •Not specified Life expectancy •Not specified Hematopoietic •Not specified Hepatic No history of chronic hepatitis requiring treatment No acute or chronic clinically significant hepatic function abnormality by physical examination or laboratory findings No known history of hepatitis A infection Renal No history of kidney disease requiring treatment No acute or chronic clinically significant kidney function abnormality by physical examination or laboratory findings Cardiovascular No acute or chronic clinically significant cardiovascular function abnormality by physical examination or laboratory findings Pulmonary
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Cancer of Cervix Using epidemiologic data drawn from a wide range of countries and population groups, investigators have found evidence of HPV in 90% to 95% of cervical cancers. The incidence of HPV in cervical cancer was 79% in our own report. Besides, 91% of high-grade CIN cases and 50% of low-grade CIN cases could be attributed to HPV infection in Taiwanese women. Because these reports for Taiwanese women were published around 10 years ago. It is important to survey and update the incidence of HPV in CIN and cervical cancer patients in Taiwanese women. We will survey the incidence of HPV infection in 500 cervical cancer patients, 100 patients of CIN and 100 normal population patients
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Cervical Cancer Healthy volunteers People infected with HPV type 16 but without CIN lesions Patients with CIN lesions Patients with cervical cancer from National Taiwan University Hospital Informed consent is obtained, and the protocols are reviewed and approved by the appropriate Investigative Review Boards
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Cervical Cancer recurrent cervical cancer 2. HPV 16 infection 3. Previously received cisplatin ot 5-FU based chemotherapy or refused to receive chemotherapy 4. HLA-A2 haplotype 5. Older than 20 years old 6. ECOG I or II 7. Life expectancy longer than 3 months 8. Adequate bone marrow reserve 9. pregnancy test: negative 10. Informed consent obtained  CNS metastasis 2. Acute or chronic infection 3. Pregnant or lactating women 4. Asthma 5. Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction 6. Autoimmune disease 7. Previously other cancers (except basal cell cancer) 8. Without chemotherapy, biotherapy for more than 6 weeks
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-74.0,  HIV Infections Sexually Transmitted Diseases for CBT or Peer Intervention Participants: 1. Female 2. Age 18-55 3. Did not inject drugs in the past 6 months 4. Self-reported sex with at least 1 male partner in the past 6 months 5. Had at least 1 of the following sexual risk factors: 1. More than 2 sex partners in the past 6 months 2. STI diagnosis in the past 6 months 3. Had a high risk sex partner in the past 90 days (i.e. a sex partner that injected drugs, smoked crack, was HIV+, or MSM) for Peer Network Participants: 1. 18 years old or older 2. One of the following: 1. Injected drugs 2. Sex partner of index 3. Social network member that the index felt comfortable talking to about HIV/STIs  for All Participants Currently enrolled in another HIV prevention intervention
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Painful Joint Prostheses Patients selected for entry into this study will be men or women of any ethnic background who are scheduled to undergo clinical and diagnostic evaluation by a member of the Department of Orthopedic Surgery at the Hospital of the University of Pennsylvania Health System or by the collaborating physicians at the Rothman Institute or the VA Philadelphia Medical Center. Study I: FDG-PET imaging in painful partial or total joint prostheses Each patient who is a candidate will be evaluated by one of the collaborators mentioned above for a painful partial or total joint prosthesis. The patient will undergo an appropriate routine evaluation including history, physical examination, radiographic, scintigraphic, and necessary laboratory evaluation. An initial diagnosis must be made for each patient. The diagnosis of loosening will be established based on clinical examination and/or radiographic evaluation demonstrating clear evidence of this complication. Other etiologies for the joint pain, except for infection and aseptic loosening, need to be excluded. Surgical intervention (prosthesis revision) may or may not be planned for the patient who is a candidate for this study. Study II: FDG-PET imaging following uncomplicated partial or total joint arthroplasty All patients fulfilling the below will be considered potential candidates for this study. Each patient must have a diagnosis of degenerative joint disease caused by osteoarthritis (no previous hip surgery) and have undergone primary partial or total joint arthroplasty by a member of the Department of Orthopedic Surgery at the Hospital of the University of Pennsylvania or referring hospitals. Other causes of degenerative joint disease will be excluded by physical, radiographic and laboratory evaluation as clinically indicated. Osteoarthritis is the most common cause of degenerative joint disease, and in order to avoid any confounding factors in experimental results that may be caused by other types of disorders, only this group of patients will be studied. A patient will be eliminated from this group at anytime if the post-operative course is complicated by any process that is thought to influence the outcome. Variations from an uncomplicated postoperative course will be determined by the operating surgeon and clinical signs or other evidence to suggest infection, early loosening, or any other process directly involving the prosthesis  Patients with other etiologies for pain, other than for infection and aseptic loosening, will be excluded from enrollment into the study
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Malignant Tumor Patients age 20 years or older 2. Patients with malignant tumor who are to be intravenously administered cisplatin as a single dose of 70 mg/m2 or more in under 3 hours 3. Patients whose performance status is 0 to 2 4. Other as specified in the study protocol  In case of patients who are previously treated with cisplatin, those having no past history of vomiting as of administration of cisplatin 2. Patients who had vomiting or dry vomiting within 24 hours before the initial administration of the moderate or severe emetic chemotherapy (including cisplatin) on Day 1 of the study 3. Pregnant women, nursing women, women of child-bearing potential, women who wish to become pregnant or women using oral contraception 4. Other as specified in the study protocol
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer biopsy-diagnosed CIN1 infection with oncogenic HPV  Any other stage of cervical abnormality pregnant or planning a pregnancy diabetic taking B vitamin supplements taking anti-epileptic treatment taking methotrexate bleeding after intercourse abnormal GI function infection with chlamydia, HIV or other agent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 35.0-65.0,  Cervical Cancer Has a cervix Never been screened for cervical cancer Not currently pregnant  Has previously had a Pap smear Has previously undergone treatment for cervical squamous intraepithelial lesion (SIL) Have lesions suspicious for cancer, have large acetowhite lesions extending over 70% of the cervix or into endocervical canal, are unsuitable for cryotherapy because of severe atrophy, polyps, cervix distorted, cervix cannot be adequately visualized Is unable to cooperate with study procedures or tolerate the insertion of a speculum